Skip to main content
Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

4. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: August 25, 2023).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed August 25, 2023.
  3. Quetiapine tablets (Seroquel®) package insert. AstraZeneca Pharmaceuticals, January 2022.
  4. Quetiapine extended-release tablets (Seroquel XR®) package insert. AstraZeneca Pharmaceuticals, January 2022.
  5. Cohrs S, Rodenbeck A, Guan Z, et. al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174:421-9.
  6. Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy tolerance in elderly patients with chronic insomnia.  Sleep. 1987;10(1):73-8.
  7. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297-307.
  8. Juri C, Chana P, Tapia J, et al. Quetiapine for insomnia in Parkinson’s disease: results from an open label trial. Clin Neuropharmacol. 2005;28(4):185-7.
  9. Fernando A, Auckland GC. Chronic insomnia secondary to chronic pain responding to quetiapine. Australas Psychiatry. 2005;13(1):86.
  10. Sokolsji KN, Brown BJ. Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. Ann Pharmacother. 2006;40:567-70.
  11. Wiegand MH, Landry F, Buckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology. 2008;196:337-8.
  12. Teran A, Majadas S, Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. Subst Use Misuse. 2008;43:2169-71.
  13. Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159-61.
  14. Cates ME, Jackson CW, Feldman JM, et al.  Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J. 2009;45:251-4.
  15. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double-blind, randomized controlled trial. J Med Assoc Thai. 2010;93(6):729-34.
  16. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. 2009;43:707-13.
  17. Anderson SL, Vande Griend JP. Quetiapine for insomnia: A review of the literature. Am J Health-Syst Pharm. 2014;71(5):394-402.
  18. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. Am J Addict. 2008;17(5):454-5.
  19. Zarowitz BJ. Quetiapine not quiet-a-pine- not a sleeper. Geriatr Nurs.  2011;32(1):46-8.
  20. Højlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry. 2022 Oct;21(3):444-451.
  21. Coe HV, Kong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother. 2012;46(5):718-22.
  22. Drugs for chronic insomnia. Med Lett Drugs Ther. 2018 Dec 17;60(1562):201-5.
  23. Agency for Healthcare Research and Quality. Off-label use of atypical antipsychotics: an update. Executive Summary. Comparative Effectiveness Review No. 43. (AHRQ Pub. No. 11-EHC087-1). Available at:  https://www.ncbi.nlm.nih.gov/books/NBK66081/pdf/Bookshelf_NBK66081.pdf. Accessed August 28, 2023.
  24. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005;22:39-54.
  25. Yang CH, Tsai SJ, Wsang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis.  J Psychopharmacol. 2005;19:661-6.
  26. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry. 2002;63(Suppl13):21-6.
  27. Texas Health and Human Services. Psychotropic medication utilization parameters for children and youth in Texas public behavioral health (6th version), June 2019. Available at: https://hhs.texas.gov/sites/default/files/documents/doing-business-with-hhs/provider-portal/facilities-regulation/psychiatric/psychotropic-medication-utilization-parameters.pdf. Accessed August 28, 2023.  
  28. Stathis S, Martin G, McKenna JG. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center.  J Clin Psychopharmacol. 2005;25:539-44.
  29. Findling RL, Reed MD, O’Riordan MA, et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder.  J Am Acad Child Adolesc Psychiatry. 2006;45:792-800.
  30. Marchand WR, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:405-11.
  31. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287-94.
  32. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003;13:295-9.
  33. Tufan AE. Adjunctive quetiapine may help depression comorbid with pervasive developmental disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1570-1.
  34. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418-28.
  35. Findling RL, Reed MD, O’Riordan MA, et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17(1):1-9.
  36. Duffy A, Milin R, Grog P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine. BMC Psychiatry. 2009;9(4).
  37. Kronenberger WG, Giauque AL, Lafata D, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-7.
  38. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.  Clin Neuropharmacol. 2011;34(6):216-9.
  39. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12:172-84.
  40. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19:563-73.